Navigation Links
Micromet to Present at the RBC Capital Markets Healthcare Conference
Date:12/5/2008

hes tested to date have been hampered by cancer cells' ability to escape recognition by T cells. The use of BiTE antibodies that are specifically designed to engage T cells for attacking cancer cells may provide a more effective anti-tumor approach than conventional monoclonal antibodies.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and our plans regarding future presentations of clinical data. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial dat
'/>"/>

SOURCE Micromet, Inc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Micromet Added to NASDAQ Biotechnology Index
2. Micromet, Inc. Reports Third Quarter 2008 Financial Results
3. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
4. Micromet Closes $40 Million Private Equity Placement
5. Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
6. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
7. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
8. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
9. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
10. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
11. Micromet to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... An article posted earlier this week by Fox News ... probiotics. The article stated that while many products are claiming ... listed, the actual use for probiotics may go beyond ... the total uses of probiotics have not yet been discovered, ... “miracle” bacterium, and debunked the myths surrounding them. , ...
(Date:6/19/2013)... June 19, 2013 ... announced the addition of the "Global ... report to their offering. ... of data protection and old security practises ... have driven the growth of biometric technologies ...
(Date:6/19/2013)... ROCKVILLE, Md. , June 19, 2013 Synthetic ... on the prevention and treatment of serious infectious diseases, announced ... the 6 th Annual OneMedForum New York Conference on ... New York City . Mr. Riley is scheduled ... live webcast of Synthetic Biologics, presentation can be accessed by ...
(Date:6/19/2013)... Calif. , June 19, 2013  Continuing its ... myocardial infarction (MI), Beckman Coulter , Inc. announces ... of its new Access AccuTnI+3 troponin I assay for ... "Clinicians have depended on Beckman Coulter,s ... new AccuTnI+3 assay has the proven performance to continue ...
Breaking Biology Technology:Natural Acne Remedy, Probiotic Action Explains the Science behind Using Probiotics for Better Health 2Global Biometric Systems Market Forecast Report - Opportunities to 2018 2Global Biometric Systems Market Forecast Report - Opportunities to 2018 3Synthetic Biologics to Present at OneMedForum New York 2013 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3
... , CINCINNATI, Sept. 18 LCA-Vision Inc. (Nasdaq: ... correction services under the Lasik Plus (R) brand, announces that ... a member of the company,s board of directors effective September ... ophthalmology industry. Management of daily operations will be the ...
... N.J., Sept. 17 Regado Biosciences, a privately held company ... announced today that the European Patent Office (EPO) has notified ... claims directed to oligonucleotide modulators of blood coagulation factor aptamers ... Company,s portfolio extends the scope and breadth of Regado,s intellectual ...
... , , , , ... The US Food and Drug Administration (FDA) has approved Valturna(R) ... two key points within the renin system, also known as the ... This is the first approval for Valturna, which is indicated for ...
Cached Biology Technology:LCA-Vision Announces CEO Resignation 2Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers 2Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers 3Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 2Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 3Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 4Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 5Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 6Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 7
(Date:6/19/2013)... DETROIT Insulin is the most potent physiological ... the storage and synthesis of lipids, protein and ... the circulatory system. It also plays a major ... where the glucose is metabolized and removed from ... understanding the precise molecular mechanisms by which insulin ...
(Date:6/19/2013)... 2013  New York College of Health Professions announces ... and Trademark Office for detecting biometric changes through smart ... have been injured, attacked or killed. This ... Intellectual Properties Agreements of New York College of Health ... New York College says, "Our ...
(Date:6/19/2013)... European Medicines Agency (EMA) approved the modified adeno-associated ... therapy for clinical use in the Western world. ... S447X for the treatment of a rare inherited ... affects approximately one or two out of one ... of the pancreas. Afflicted individuals carry a defect ...
Breaking Biology News(10 mins):Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4No danger of cancer through gene therapy virus 2
... Common colds typically cause a week of sneezing, aches and ... and a few used sick days behind. But what if ... adenovirus type-3 is known as the "uncommon cold" because the ... to those of the common cold which is caused by ...
... of Census of Marine Life explorations as scientists uncover ... the global ocean. A world of marine discoveries including ... star, and Antarctica,s biggest-ever amphipod and other interesting, rare, ... http://earth.google.com/ocean . Or one can follow along on scientific ...
... been born 200 years ago come Feb. 12, but his ... And while the Origin of Species author might not have ... that the environment is changing. He would, however, be astonished ... "Every species is under temporary permanence," says Bill Saidel, ...
Cached Biology News:New vaccine developed for preventing 'uncommon cold' virus 2Evolution and climate change research advances at Rutgers-Camden 2
... the smallest thermal cyclers on the market, which ... 0.5ml (20 samples) or 0.2ml microtube (25 samples) ... and cooling rate of 3.6C/sec and 2.0C/sec respectively ... Fast track programming with new quick dial facility ...
... HRP Conjugate Stabilizer is an aqueous solution ... other non-toxic stabilizing chemicals in a MOPS ... 6.7. This product contains a combination ... ppm Proclin 300 (Rohm and Haas Company) ...
Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
Biology Products: